Lineage Cell Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lineage Cell Therapeutics (LCTX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$5Upside to Avg. PT+434.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 14, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
May 4, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$3
Apr 28, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$9
Mar 25, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$3→$4
Mar 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
Mar 6, 2026	D. Boral Capital	Jason Kolbert	PT Raise	Buy	$2→$3
Feb 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Nov 25, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Nov 24, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
Aug 27, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Aug 14, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Aug 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Jun 23, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Jun 23, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
Mar 14, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$4→$3
Mar 11, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$2
Mar 11, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
Feb 11, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9
Feb 11, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$3→$2
Jan 31, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$9

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know

Benzinga Insights

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.

Benzinga Newsdesk

Lineage Cell Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lineage Cell Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

People Also Watch

People Also Watch

Lineage Cell Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lineage Cell Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

PROD. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

PROD. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

PROHC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know

PROD. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

PRO
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target